These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 18303482)

  • 21. Novel cancer therapies: treatments driven by tumour biology.
    Ramaswami R; Harding V; Newsom-Davis T
    Postgrad Med J; 2013 Nov; 89(1057):652-8. PubMed ID: 24129032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC).
    Papatsoris AG; Karamouzis MV; Papavassiliou AG
    Curr Med Chem; 2005; 12(3):277-96. PubMed ID: 15723619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-targeting driver pathways in prostate cancer: two birds with one stone.
    Zoubeidi A; Gleave ME
    EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29572264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
    Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
    Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multidisciplinary approach to the management of hormone-refractory prostate cancer.
    Taneja SS
    Rev Urol; 2003; 5 Suppl 3(Suppl 3):S85-91. PubMed ID: 16985956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multidisciplinary approach to the management of hormone-refractory prostate cancer.
    Taneja SS
    Rev Urol; 2003; 5 Suppl 2(Suppl 2):S53-9. PubMed ID: 16986048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment options for hormone-refractory prostate cancer.
    Chang SS
    Rev Urol; 2007; 9 Suppl 2(Suppl 2):S13-8. PubMed ID: 17554405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus.
    Moussavi M; Tearle H; Fazli L; Bell JC; Jia W; Rennie PS
    Mol Ther; 2013 Apr; 21(4):842-8. PubMed ID: 23337981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioengineered viral vectors for targeting and killing prostate cancer cells.
    Zhang KX; Jia W; Rennie PS
    Bioeng Bugs; 2010; 1(2):92-6. PubMed ID: 21326934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and SAR exploration of N-aryl-N-(3-aryl-1,2,4-oxadiazol-5-yl)amines as potential therapeutic agents for prostate cancer.
    Krasavin M; Rufanov KA; Sosnov AV; Karapetian R; Godovykh E; Soldatkina O; Lavrovsky Y; Gakh AA
    Chem Cent J; 2010 Mar; 4():4. PubMed ID: 20214785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell signaling modifiers in prostate cancer.
    Chen FL; Armstrong AJ; George DJ
    Cancer J; 2008; 14(1):40-5. PubMed ID: 18303482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
    Majumder PK; Febbo PG; Bikoff R; Berger R; Xue Q; McMahon LM; Manola J; Brugarolas J; McDonnell TJ; Golub TR; Loda M; Lane HA; Sellers WR
    Nat Med; 2004 Jun; 10(6):594-601. PubMed ID: 15156201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.